metaPreg - Levetiracetam (Epilepsy) during pregnancy

Levetiracetam (Epilepsy)

Table Graphic exposition period:

Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Congenital malformations
All congenital malformations (majors, minors, majors and minors, or unspecified)	1.01 [0.78, 1.31]	0%	12 studies	148,227	2,691	low	ROB	-
Major congenital malformations	1.01 [0.78, 1.31]	0%	11 studies	148,227	2,681	low	ROB	-
Congenital heart defects	1.33 [0.64, 2.78]	0%	4 studies	40	1,177	not evaluable	ROB	-
Digestive system anomalies	2.24 [0.25, 20.02]	0%	2 studies	4	128	not evaluable	ROB	-
Hypospadias	1.28 [0.27, 6.13]	0%	3 studies	13	1,071	not evaluable	ROB	-
Limb defects	3.89 [0.74, 20.42]	0%	2 studies	6	128	not evaluable	ROB	-
Neural Tube Defects	2.59 [0.50, 13.52]	0%	3 studies	5	1,071	not evaluable	ROB	-
Oro-facial clefts	1.34 [0.20, 9.12]	32%	3 studies	12	1,071	not evaluable	ROB	-
Spina bifida	3.67 [0.34, 39.26]	0%	2 studies	3	177	not evaluable	ROB	-
Urinary malformations	0.53 [0.12, 2.33]	0%	2 studies	16	705	not evaluable	ROB	-
4 non statistically significant endpoints reported in only one study
Growth parameters and prematurity
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Preterm (< 37 weeks)	1.52 [1.16, 1.98]	0%	6 studies	91,430	822	not evaluable	ROB	2.40 [1.60; .]
Small for gestational age (weight)	1.21 [0.89, 1.64]	43%	6 studies	167,528	1,822	not evaluable	ROB	-
Low birth weight (< 2500g)	1.98 [1.36, 2.88]	5%	2 studies	91,582	634	not evaluable	ROB	3.37 [2.06; .]
Large for gestational age (weight)	1.28 [0.13, 12.96]	0%	2 studies	71	23	not evaluable	ROB	-
Very preterm (28 to 32 weeks)	1.10 [0.20, 5.96]	51%	2 studies	8,593	718	not evaluable	ROB	-
Extremely preterm (< 28 weeks)	1.01 [0.19, 5.41]	0%	2 studies	2,043	718	not evaluable	ROB	-
Macrosomia (> 4000g)	0.67 [0.56, 0.80]	-	1 study	577,255	621	not evaluable	ROB	2.35 [.; 1.80]
Maternal consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Caesarean	1.50 [0.67, 3.41]	0%	2 studies	365	41	not evaluable	ROB	-
Amniotic fluid problems (polyhydramnios and/or oligohydramnios)	1.20 [0.07, 20.23]	0%	2 studies		27	not evaluable	ROB	-
Gestational diabetes	0.37 [0.04, 3.82]	0%	2 studies	2	27	not evaluable	ROB	-
4 non statistically significant endpoints reported in only one study
Neonatal disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Neonatal medical care	1.50 [0.63, 3.59]	0%	3 studies	170	92	not evaluable	ROB	-
Neonatal disorders (as a whole)	1.06 [0.85, 1.33]	0%	2 studies	222,315	691	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study
Long term consequences
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Child/Infant death (> 28 days of life)	2.96 [0.53, 16.41]	35%	2 studies	4,703	634	not evaluable	ROB	-
Emotional disorders	1.29 [0.67, 2.49]	58%	3 studies	503	1,131	not evaluable	ROB	-
Behavioral disorders	0.79 [0.43, 1.45]	0%	2 studies	19	70	not evaluable	ROB	-
Intrauterine deaths
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Intrauterine deaths (as a whole or unspecified)	1.15 [0.78, 1.69]	0%	6 studies	202	656	not evaluable	ROB	-
Late intrauterine deaths (> 22 weeks)	1.72 [0.43, 6.99]	0%	5 studies	9	371	not evaluable	ROB	-
Perinatal death	2.47 [0.31, 19.60]	0%	2 studies	13	309	not evaluable	ROB	-
Early intrauterine death (< 22 weeks)	1.10 [0.72, 1.68]	0%	3 studies	173	339	not evaluable	ROB	-
Elective/induced termination of pregnancy	0.44 [0.03, 7.32]	0%	2 studies		84	not evaluable	ROB	-
Neuro-developmental disorders
Adverse outcome	OR 95%CI	I2	k	No. cases	No. exposed	publication bias	ROB	E-value
Language disorders/delay	0.89 [0.68, 1.16]	0%	7 studies	72,083	851	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis/Risk	1.73 [0.74, 4.04]	51%	4 studies	4,651	1,724	not evaluable	ROB	-
ASD (Autism spectrum disorder): Diagnosis	1.28 [0.57, 2.85]	32%	3 studies	4,620	1,712	not evaluable	ROB	-
Neuro-developmental disorders (as a whole)	1.08 [0.65, 1.80]	0%	3 studies	10,470	1,636	not evaluable	ROB	-
Cognitive developmental disorders/delay (< 3 years old)	1.56 [0.51, 4.80]	47%	3 studies	23	109	not evaluable	ROB	-
Psychomotor developmental disorders/delay	1.08 [0.53, 2.22]	29%	3 studies	9	109	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis/Risk	1.18 [0.58, 2.39]	46%	3 studies	547	1,133	not evaluable	ROB	-
ASD (Autism spectrum disorder): Risk	2.39 [0.45, 12.72]	46%	2 studies	36	40	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Diagnosis	1.17 [0.24, 5.62]	39%	2 studies	547	1,091	not evaluable	ROB	-
ADHD (Attention deficit hyperactivity disorder): Risk	0.91 [0.47, 1.79]	0%	2 studies	7	70	not evaluable	ROB	-
2 non statistically significant endpoints reported in only one study